-

Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2023 financial results on Thursday, May 11th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 11th, at 8:30 a.m. ET.

Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Relations:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Charles River Laboratories International, Inc.

NYSE:CRL

Release Summary
Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call
Release Versions
$Cashtags

Contacts

Investor Relations:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

More News From Charles River Laboratories International, Inc.

Charles River Highlights Effectiveness of VCGs in Toxicology

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) has shared the results of a retrospective analysis in Regulatory Toxicology and Pharmacology, showing that virtual control groups (VCGs) can preserve scientific integrity while reducing reliance on animal models. The review, which looked at 20 toxicology studies that replaced concurrent control groups (CCGs) with curated VCGs, and compared the outcomes across study-level decisions and detailed endpoin...

Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call...

Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with the American Heart Association, the world’s leading nonprofit organization focused on heart and brain health, to support cardiovascular disease awareness, prevention, and community health initiatives. “New data from the American Heart Association shows that cardiovascular disease continues to take an enormous toll on families and communities,” said Kristen Eisenhau...
Back to Newsroom